Strategy | Financing Highlight
Private Placement / Financing Transactions
Vesalius Therapeutics: The company raised $75 million of Series A venture funding from Flagship Pioneering on March 1, 2022. The company is a developer of a biotechnology platform intended to treat common illnesses.
Rondo Therapeutics: The company raised $67 million of Series A venture funding in a deal led by Red Tree Venture Capital and Canaan Partners on March 2, 2022. Johnson & Johnson Innovation – JJDC, Novo Holdings, and SV Health Investors also participated in the round. The company is a developer of bispecific therapeutic antibodies designed to control the activation of the immune system to fight cancer.
Qventus: The company raised $50 million through Series C venture funding in a deal led by Premier and Thomas H. Lee Partners on February 28, 2022, putting the company’s pre-money valuation at $150 million. The company is a developer of hospital management software designed for hospital teams to make more effective operational decisions in real-time.
SeLux: The company raised $48.2 million of Series C2 venture funding in a deal led by RA Capital Management on February 28, 2022, putting the company’s pre-money valuation at $110 million. Schooner Capital, Sands Capital, Northpond Ventures, and other undisclosed investors also participated in the round. The company is a developer of a biotechnology platform designed for antibiotic susceptibility testing and diagnostics of infectious diseases.
Inceptor Bio: The company raised $43.3 million of venture funding from undisclosed investors on March 4, 2022. The company is a developer of a biotech platform intended for advancing research and developing therapies to cure cancer.
Epsilogen: The company raised GBP 30.8 million of Series B venture funding in a deal led by Novartis Venture Fund on March 2, 2022. British Patient Capital and other investors also participated in the round. The company is an operator of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
OncXerna Therapeutics: The company raised $30 million of venture funding from undisclosed investors on March 3, 2022. The company is a developer of cancer therapies intended to improve the long-term survival of cancer patients worldwide.
Supira Medical: The company raised $30 million of Series C venture funding in a deal led by The Capital Partnership and Cormorant Asset Management on February 28, 2022, putting the company’s pre-money valuation at $170 million. Picard Angst MedTech, 415 CAPITAL, AMED Ventures, and other undisclosed investors also participated in the round. The company is a developer of a percutaneous ventricular assist device designed to treat high-risk coronary intervention and cardiogenic shock.
Synapse Medicine: The company raised $28 million of venture funding in a deal led by Korelya Capital on March 1, 2022. BNP Paribas Développement, Groupe MACSF, Siparex XAnge Venture, and MUTUELLES IMPACT also participated in the round. The company is a developer of a medical intelligence platform designed to assist doctors in managing drug prescriptions.
ChromaCode: The company raised $28 million of venture funding from undisclosed investors on March 3, 2022. The company is an operator of a molecular diagnostics company intended to redefine molecular testing through data science.
Modulus: The company raised $20.4 million of Series C venture funding from Heights Capital Management, Jafco, and Keio Innovation Initiative on March 1, 2022. UTokyo Innovation Platform, SBI Investment, and Green Co-Invest Investment also participated in the round. The company is an operator of a pre-clinical stage drug discovery company designed to accelerate the discovery of new medicines.
Stämm: The company raised $17 million of Series A venture funding in a deal led by Varana Capital on March 1, 2022. Abundance Investment, Vista Equity Partners, SOSV, Draper Associates, Draper Cygnus, Teramips Technologies, Dragones Venture Partners, Grid Exponential, Trillian, Vista Energy, Serenity Traders, Decarbonization Consortium, and other undisclosed investors also participated in the round. The company is a developer of a novel bioproduction system designed to scale up the biotech industry using microfluidics, electroporation, and robotics.
Pristine Surgical: The company raised $15 million of Series D venture funding in a deal led by Ceros Capital Markets on March 3, 2022. Other undisclosed investors also participated in the round. The company is a developer of a digital visualization platform designed to improve the surgical episode for patients, surgeons, and centers in endoscopic procedures.
CancerIQ: The company raised $14 million through Series B funding in a deal led by Merck Global Health Innovation Fund and Amgen Ventures on March 3, 2022, putting the company’s pre-money valuation at $36 million. McKesson Ventures, OSF Ventures, HealthX Ventures, and other undisclosed investors also participated in the round. The company is a developer of a precision health technology designed for doctors to identify and manage patients at high risk for cancer.
Walking Fish Therapeutics: The company raised $12.7 million of venture funding from ShangPharma Innovation, and undisclosed investors on March 3, 2022. The company is a developer of cell-based therapeutics designed to treat serious diseases.
MIP Diagnostics: The company raised GBP 7.3 million of venture funding in a deal led by Calculus Capital, BGF, and Downing Ventures on March1, 2022. Mercia Asset Management, Andrew Fisher, and other undisclosed investors also participated in the round. The company is a developer of molecular imprinted polymers (MIPS) and nanoMIPs plastic antibodies technology designed to circumvent the drawbacks of traditional MIP manufacturing methods.
LightDeck: The company raised $6.1 million of venture funding from twelve undisclosed investors on March 3, 2022. The company is a developer of on-the-spot diagnostic products designed to offer fast, accurate, simple, and low-cost diagnostic tests.
Bluegrass Vascular Technologies: The company raised $5 million of venture funding in the form of convertible debt from undisclosed investors on March 3, 2022. The company is a manufacturer of a medical device intended to address limitations in vascular access procedures.
ImmunoVec: The company raised $4.3 million of venture funding from undisclosed investors on March 2, 2022. The company is a developer of a gene therapy intended for hematopoietic diseases.
Access Point Technologies EP: The company raised an undisclosed amount of venture funding from Stony Lonesome Group in approximately March 2022. The company is a developer of proprietary medical devices intended for the electrophysiology market.
Optimal: The company raised an undisclosed amount of venture funding from Nova Growth Capital in approximately March 2022. The company is a developer of a healthcare platform intended to help parents track their child’s symptoms to reduce hospital visits and improve their medical care.
Pluto Health: The company raised an undisclosed amount of venture funding from Boston Millennia Partners, Shields Capital, and Sierra Ventures on March 3, 2022. The company is a developer of a multi-functional consumer health technology application designed to aggregate EHR data.
M&A Transactions
DigitalBridge / Aurora Health Network: The wellness infrastructure business of Digital Bridge was acquired by Highgate Hotels and Aurora Health Network for $3.2 billion on February 28, 2022. The company is an operator of a wellness infrastructure business based in Boca Raton, Florida.
Syndesi Therapeutics / AbbVie: The company was acquired by AbbVie for $1 billion on March 1, 2022. The company is a developer of drug molecules designed to treat cognitive impairment.
Alpaca Audiology / Sonova: The company was acquired by Sonova for $310 million on March 1, 2022. The company is an operator of a network of audiological care clinics across the United States.
Abcore / Fortis Life Sciences: The company was acquired by Fortis Life Sciences for an undisclosed amount on March 2, 2022. The company is an operator of an antibody discovery platform designed to specialize in nanobody technology.
Amarsi Assisted Living / The Ensign Group: The company was acquired by The Ensign Group for an undisclosed amount on March 1, 2022. The company is an operator of a skilled nursing facility intended to offer a home-style caring environment for elderly people.
Amici Clinical Research / IMA Clinical Research: The company was acquired by IMA Clinical Research, a subsidiary of The IMA Group, for an undisclosed amount on March 2, 2022. The company is an operator of a clinical research center dedicated to enhance longevity and quality of life through clinical research investigating.
Care-wing / M3: The company was acquired by M3 for an undisclosed amount on March 1, 2022. The company is a developer of a care recording software intended to assist helpers to check on their daily schedules and service details on their smartphones and to easily report on the services they have implemented.
Diopsys / LumiThera: The company was acquired by LumiThera for an undisclosed amount on March 5, 2022. The company is a producer of visual electrophysiology and non-invasive diagnostic vision testing systems designed to provide vision disorder detection and vision testing services.
Dynasty Medical Laboratory Services / Diversified Medical Healthcare: The company was acquired by Diversified Medical Healthcare for an undisclosed amount on March 3, 2022. The company is a provider of laboratory testing services based in Hurricane, Utah.
Healthcare Resource Group / Computer Programs & Systems: The company was acquired by Computer Programs & Systems for an undisclosed amount on March 1, 2022. The company is a provider of patient financial services designed to optimize accounts receivables.
Medical Associates / Summit Medical Group: The company was acquired by Summit Medical Group, a subsidiary of CityMD, on March 1, 2022, for an undisclosed amount. The company is a provider of healthcare services intended to serve patients with long-term illnesses.
Pharmapar / Nora Pharma: The company was acquired by Nora Pharma for an undisclosed amount on February 28, 2022. The company is a distributor of generic pharmaceutical products intended to improve the financial health of pharmacies.
Piedmont Augusta Hospital / Piedmont Healthcare: The company was acquired by Piedmont Healthcare for an undisclosed amount on March 1, 2022. The company is a provider of healthcare services intended to serve patients in greater Augusta, Georgia.
SureAdhere / Dimagi: The company was acquired by Dimagi for an undisclosed amount on March 2, 2022. The company is a developer of a mobile health platform intended to enable remote medication adherence monitoring through video technology for patients.
The Waterton Healthcare and Rehabilitation / The Ensign Group: The company, a subsidiary of Southwest LTC, was acquired by The Ensign Group for an undisclosed amount on March 1, 2022. The company is an operator of a skilled nursing facility intended to offer a home-style caring environment for elderly people.
________________________________________
Connect on LinkedIn with Jonathan Hodson-Walker
Silverwood Partners Team
Jonathan Hodson-Walker
Managing Partner
T: 508-651-2194
Chuck Slotkin
Managing Director
T: 508-651-2194
Interested in becoming an Industry Advisor?
Silverwood Partners is actively expanding the Firm’s Industry Advisor team. If you have an interest in working as part of the Silverwood team in a deal-oriented advisor capacity, please contact Jonathan Hodson-Walker directly. For more information on the Silverwood Industry Advisor opportunity, please follow the link below. We look forward to hearing from you. Click here to learn more.